CBS 2019
CBSMD教育中心
中 文

DAPT Duration

Abstract

Recommended Article

Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the State of the art: duration of dual antiplatelet therapy after percutaneous coronary intervention and coronary stent implantation – past, present and future perspectives A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trial Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score Impact of age on the comparison between short-term vs 12-month dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-Year follow-up results of the REDUCE trial
|<< 1 2 3 4 5 6 7 ...>>|

JOURNAL：CBS2017 Article Link

Make a Voice to the World

CBS2017


Denver - October 29, from 11 to 11:30 a.m., Dr Peter Block gave Prof Shao-Liang Chen from Nanjing First Hospital an in-depth interview in the Colorado Convention Center at TCT2017 (Transcatheter Cardiovascular Therapy conference). Prof Shao-Liang Chen is the initiator of DK Crush-V, which using randomized, prospective, multinational design to evaluate the efficacy and safety of DK crush over provisional side branch stenting for patients with unprotected left main bifurcation lesions.


With the further development of interventional devices , coronary bifurcation lesions remains as the one of the most challenging cardiovascular diseases to be tackled. Varies of treatment strategies need high reliability, high level of evidence before promoted in global clinical practices. With passion and faith for better clinical outcome, Prof Chen and his research team keep working on this issue over ten years, seeking a better treatment strategy  for unprotected left main bifurcation lesions. This time, he share his professional clinical experiences and perspectives with international colleagues about the "Current practice and perspectives on treatment in left main bifurcation in China" at TCT2017.






As the leading event in the fields of left main coronary artery disease and transcatheter valve disease, this year, TCT2017 presents 12 LBCTs and 16 FRIs to cause attention.  The progress of DK-V is one of the most notable results, which will be released on October 30th at 11:40 am, local time (at 1:40 a.m. on November 1, Beijing time).



Important Events at TCT2017





>CBS CBS 2019

> CBS 2019 REGISTRATION

> CBS 2019 PROGRAM

> CBS 2019 CALL FOR SCIENCE

> CBS 2019 SPOTLIGHTS

 CBSMD

> CBSMD WEBSITE REGISTRATION

> EDUCATION CENTER

> RECOMMANDED PAPER

> TOP 10 RESEARCH PAPER

> PRE-READING

CBS 2019 CBS 2019 FACULTY Education Resource CBSMD Scientific Library
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top